Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (6): 646-649.DOI: 10.3969/j.issn.1673-8640.2021.06.015
Previous Articles Next Articles
Received:2020-03-18
Online:2021-06-30
Published:2021-06-30
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.06.015
| 组别 | 例数 | P-选择素/（μg/L） | ICAM-1/（μg/L） | IL-17A/（ng/L） |
|---|---|---|---|---|
| 正常对照组 | 62 | 19.35±2.86 | 16.12±5.59 | 232.72±21.31 |
| HBV感染组 | ||||
| 慢性乙肝组 | 82 | 50.51±3.53* | 12.73±1.26* | 410.32±28.59* |
| 肝硬化组 | 21 | 73.14±5.10*# | 18.65±1.18*# | 501.65±32.58*# |
| HCC组 | 29 | 65.63±6.01*#△ | 10.91±1.07*#△ | 389.34±30.12*#△ |
| F值 | 90.11 | 75.63 | 105.69 | |
| P值 | <0.01 | <0.01 | <0.01 |
| 组别 | 例数 | P-选择素/（μg/L） | ICAM-1/（μg/L） | IL-17A/（ng/L） |
|---|---|---|---|---|
| 正常对照组 | 62 | 19.35±2.86 | 16.12±5.59 | 232.72±21.31 |
| HBV感染组 | ||||
| 慢性乙肝组 | 82 | 50.51±3.53* | 12.73±1.26* | 410.32±28.59* |
| 肝硬化组 | 21 | 73.14±5.10*# | 18.65±1.18*# | 501.65±32.58*# |
| HCC组 | 29 | 65.63±6.01*#△ | 10.91±1.07*#△ | 389.34±30.12*#△ |
| F值 | 90.11 | 75.63 | 105.69 | |
| P值 | <0.01 | <0.01 | <0.01 |
| 组别 | 例数 | P-选择素（μg/L） | ICAM-1（μg/L） | IL-17A（ng/L） |
|---|---|---|---|---|
| 轻度组 | 19 | 50.08±4.67 | 12.17±4.38 | 357.12±23.41 |
| 中度组 | 45 | 63.21±6.34* | 28.03±3.24* | 410.38±26.67* |
| 重度组 | 18 | 70.35±7.13*# | 35.67±2.06*# | 472.03±28.82*# |
| F值 | 15.43 | 32.61 | 20.03 | |
| P值 | <0.01 | <0.01 | <0.01 |
| 组别 | 例数 | P-选择素（μg/L） | ICAM-1（μg/L） | IL-17A（ng/L） |
|---|---|---|---|---|
| 轻度组 | 19 | 50.08±4.67 | 12.17±4.38 | 357.12±23.41 |
| 中度组 | 45 | 63.21±6.34* | 28.03±3.24* | 410.38±26.67* |
| 重度组 | 18 | 70.35±7.13*# | 35.67±2.06*# | 472.03±28.82*# |
| F值 | 15.43 | 32.61 | 20.03 | |
| P值 | <0.01 | <0.01 | <0.01 |
| 项目 | β值 | 标准误 | Wald值 | OR值（95%CI） | P值 |
|---|---|---|---|---|---|
| P-选择素 | 0.82 | 0.88 | 15.23 | 9.21（1.82~18.82） | <0.01 |
| ICAM-1 | 0.80 | 0.76 | 12.15 | 8.01（1.51~15.55） | <0.01 |
| IL-17A | 0.75 | 0.72 | 10.56 | 5.23（1.19~14.48） | <0.01 |
| 项目 | β值 | 标准误 | Wald值 | OR值（95%CI） | P值 |
|---|---|---|---|---|---|
| P-选择素 | 0.82 | 0.88 | 15.23 | 9.21（1.82~18.82） | <0.01 |
| ICAM-1 | 0.80 | 0.76 | 12.15 | 8.01（1.51~15.55） | <0.01 |
| IL-17A | 0.75 | 0.72 | 10.56 | 5.23（1.19~14.48） | <0.01 |
| 项目 | AUC（95%CI） | 敏感性/% | 特异性/% | 阳性预测值/% | 阴性预测值/% |
|---|---|---|---|---|---|
| P-选择素 | 0.807（0.742~0.872） | 79.65 | 71.25 | 79.56 | 75.36 |
| ICAM-1 | 0.700（0.620~0.780） | 72.36 | 73.98 | 75.21 | 74.01 |
| IL-17A | 0.672（0.591~0.754） | 70.26 | 75.52 | 70.14 | 72.36 |
| 项目 | AUC（95%CI） | 敏感性/% | 特异性/% | 阳性预测值/% | 阴性预测值/% |
|---|---|---|---|---|---|
| P-选择素 | 0.807（0.742~0.872） | 79.65 | 71.25 | 79.56 | 75.36 |
| ICAM-1 | 0.700（0.620~0.780） | 72.36 | 73.98 | 75.21 | 74.01 |
| IL-17A | 0.672（0.591~0.754） | 70.26 | 75.52 | 70.14 | 72.36 |
| [1] | 张若梅, 刘先勇. 糖皮质激素在重度慢性乙型病毒性肝炎治疗中的应用[J]. 医药导报, 2020,39(2):199-201. |
| [2] |
TERRAULT N A, LOK A S F, MCMAHON B J, et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018,67(4):1560-1599.
DOI URL |
| [3] | 张丽翠, 钟晨, 张砚, 等. 恩替卡韦治疗慢性乙型病毒性肝炎患者的临床研究[J]. 中国临床药理学杂志, 2019,35(20):2539-2542. |
| [4] |
BERTOLETTIA , LE BERT N. Immunotherapy for chronic hepatitis B virus infection[J]. Gut Liver, 2018,12(5):497-507.
DOI URL |
| [5] | 王烈, 胡义忠, 徐秀亮, 等. 血清sP-selectin、sICAM-1和免疫球蛋白检测对乙肝肝硬化预后评估的意义[J]. 中国免疫学杂志, 2017,33(11):1699-1705. |
| [6] | 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019,27(12):938-961. |
| [7] |
MERLE N S, GRUNENWOLD A, RAJARATNAM H, et al. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles[J]. JCI Insight, 2018,3(12):e96910.
DOI URL |
| [8] |
IANNACONE M. Platelet-mediated modulation of adaptive immunity[J]. Semin Immunol, 2016,28(6):555-560.
DOI URL |
| [9] |
BHAT A, DAS S, YADAV G, et al. Hyperoxidized albumin modulates platelets and promotes inflammation through CD36 receptor in severe alcoholic hepatitis[J]. Hepatol Commun, 2019,4(1):50-65.
DOI URL |
| [10] |
ALI R O, MOON M S, TOWNSED E C, et al. Exploring the link between platelet numbers and vascular homeostasis across early and late stages of fibrosis in hepatitis C[J]. Dig Dis Sci, 2020,65(2):524-533.
DOI URL |
| [11] |
ZHANG H, ZHANG S, ZHANG J, et al. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism[J]. Platelets, 2020,31(8):1019-1027.
DOI URL |
| [12] |
TANA M M, ZHAO X, BRADSHAW A, et al. Factors associated with the platelet count in patients with chronic hepatitis C[J]. Thromb Res, 2015,135(5):823-828.
DOI URL |
| [13] | 杨斌, 张海泉, 于鲜君, 等. 细胞间黏附分子-1在肝癌组织中表达及临床意义[J]. 临床军医杂志, 2019,47(9):920-922. |
| [14] | 陈曦, 胡冬, 吴丹, 等. 慢性乙肝患者血清可溶性黏附分子P-selectin、ICAM-1与病情变化的相关性研究[J]. 海南医学院学报, 2018,24(24):2153-2157. |
| [15] |
ELSHEREDY A G, ALMAEEN A H, GHAZY A A, et al. Impact of interleukin 28B and ICAM-1 genetic polymorphisms on response to direct antiviral treatment among HCV infected patients[J]. Endocr Metab Immune Disord Drug Targets, 2020,20(8):1328-1335.
DOI URL |
| [16] | CASTELLI G, PELOSI E, TESTA U. Liver cancer:molecular characterization,clonal evolution and cancer stem cells[J]. Cancers(Basel), 2017,9(9):127. |
| [17] | 操伟庆, 季榕. 慢性乙型肝炎患者血清中IL-17A和TGF-β1水平的变化及意义[J]. 贵州医科大学学报, 2017,42(12):1431-1435. |
| [18] | 王凌旭. T细胞17与IL-17在慢性乙肝患者血清中的表达意义[J]. 医药论坛杂志, 2016,37(9):83-84. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
